In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
AbCellera Biologics Inc (NASDAQ: ABCL) closed the day trading at $3.84 down -4.95% from the previous closing price of $4.04. In other words, the price has decreased by -$4.95 from its previous closing price. On the day, 1.33 million shares were traded. ABCL stock price reached its highest trading level at $4.199 during the session, while it also had its lowest trading level at $3.78.
Ratios:
For a better understanding of ABCL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.75 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 26 ’23 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26 ’23. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1128656640 and an Enterprise Value of 499634880. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.54 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 13.14 whereas that against EBITDA is -2.348.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.44, which has changed by -0.31409168 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $8.05, while it has fallen to a 52-week low of $3.62. The 50-Day Moving Average of the stock is -13.06%, while the 200-Day Moving Average is calculated to be -22.98%.
Shares Statistics:
Over the past 3-months, ABCL traded about 1.40M shares per day on average, while over the past 10 days, ABCL traded about 1660910 shares per day. A total of 290.82M shares are outstanding, with a floating share count of 205.97M. Insiders hold about 29.92% of the company’s shares, while institutions hold 37.52% stake in the company. Shares short for ABCL as of 1713139200 were 23091848 with a Short Ratio of 16.44, compared to 1710460800 on 23039087. Therefore, it implies a Short% of Shares Outstanding of 23091848 and a Short% of Float of 10.22.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.25, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.5 and -$1.01 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.7, with 6.0 analysts recommending between -$0.45 and -$0.99.
Revenue Estimates
8 analysts predict $9.95M in revenue for the current quarter. It ranges from a high estimate of $18.29M to a low estimate of $8.9M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $12.19MFor the next quarter, 8 analysts are estimating revenue of $11.49M. There is a high estimate of $17.36M for the next quarter, whereas the lowest estimate is $9.22M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $77.46M, while the lowest revenue estimate was $36.9M, resulting in an average revenue estimate of $47.55M. In the same quarter a year ago, actual revenue was $38.02MBased on 6 analysts’ estimates, the company’s revenue will be $67.86M in the next fiscal year. The high estimate is $117.86M and the low estimate is $46.4M.
